Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01096290 · ClinicalTrials.gov registry record · Phase 4
Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications
A Phase 4 study, sponsored by University of South Alabama.
- Terminated
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
NCT01096290: Clinical Trial Phase 4 study, sponsored by University of South Alabama.
NCT01096290 is a Phase 4 study that was terminated before completion, run by University of South Alabama. The registered enrollment target is 23 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01096290, a Phase 4 study, was terminated before completion, sponsored by University of South Alabama.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
Study Summary
Constipation from medications is a serious and common condition. Lubiprostone has properties that make it a candidate drug. One hundred volunteers with constipation who are taking medications known to cause constipation will be randomized to take lubiprostone or placebo for 28 days. Therapeutic outcome will be evaluated by investigator and study subject assessment.
Primary Outcome
Subjects will report symptoms by questionnaire
Interventions
- DRUG Matched placebo
- DRUG lubiprostone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-04 |
| Est. Completion | 2012-09 |
| Phase | Phase 4 |
Why NCT01096290 stopped before completion
NCT01096290 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Matched placebo is the first listed.
NCT01096290 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01096290 about?
NCT01096290 is a clinical study titled "Comparison of Lubiprostone and Placebo for the Relief of Constipation From Constipating Medications". Constipation from medications is a serious and common condition. Lubiprostone has properties that make it a candidate drug. One hundred volunteers with constipation who are taking medications known to cause constipation will be randomized to take lubiprostone or placebo for 28 days. Therapeutic outc...
What is the current status of trial NCT01096290?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2010-04. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01096290?
The interventions under investigation include: Matched placebo (DRUG), lubiprostone (DRUG).
Who is sponsoring clinical trial NCT01096290?
This trial is sponsored by University of South Alabama, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01096290's enrollment target sits among peer trials
23 1725th of 2000 higher than 270 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia